Post-transplant lymphoproliferative disorder (PTLD) is a well-recognized complication after solid organ and hematopoietic stem cell transplantations (HSCT). The majority are of B-cell origin and Epstein-Barr virus (EBV) related. 1 PTLD of T-cell origin have also been described after solid organ transplantations, but are mostly unrelated to EBV infection. After allogeneic HSCT, three cases of T-cell PTLD have been reported. 2 Recently, two cases of T-cell PTLD following autologous HSCT were described. 3, 4 We report another case of T-cell PTLD after autologous HSCT in a patient with nonsecretory multiple myeloma (MM).
A 68-year-old man presented with worsening back pain. Physical examination showed no lymphadenopathy or hepatosplenomegaly. Initial investigations revealed anemia, thrombocytopenia, hypercalcemia, renal impairment, multiple vertebral compression fractures and immune paresis without detectable serum monoclonal bands and urine light chains. The bone marrow (BM) was replaced by malignant plasma cells and stage IIIB nonsecretory MM was diagnosed. He was commenced on the VAD (vincristine, adriamycin and dexamethasone) regimen.
BM assessment after five cycles of VAD revealed normal cellularity with 2% of plasma cells. We collected his peripheral blood (PB) stem cells (SC) using cyclophosphamide and G-CSF. At 6 months after the initial diagnosis, he received high-dose melphalan (200 mg/m 2 ) followed by unmanipulated SC infusion (total dose: 5.51 Â 10 6 /kg). Neutrophil recovery occurred on day þ 15 and he was independent of platelet transfusions from day þ 10. On day þ 40, we noted a peripheral lymphocytosis. This persisted over the next 12 months and ranged from 57.9 to 74.5% of the total white cells. He remained clinically well without organomegaly more than 12 months after HSCT.
On the PB film, 80% of the lymphocytes were large granular lymphocytes (LGL). This was confirmed on flow cytometric analysis, where 80% of the peripheral lympho-
and CD56À. BM examination revealed a lymphocytic infiltrate (30% of total nucleated cells) and no evidence of plasmacytic expansion. The majority (90%) of the lymphocytes had the above antigenic expression. Cytogenetic study revealed normal male karyotype. Monoclonal rearrangement of the TCR-b gene was detected from both PB and BM mononuclear cells ( Figure 1 ). Serological tests for human immunodeficiency virus (HIV), hepatitis B and C viruses were negative. Polymerase chain reactions for cytomegalovirus (CMV) were negative. The EBV serology was positive for IgG but negative for IgM. EBV DNA was not detected. EBV-encoded small nuclear RNA (EBER) in situ hybridization performed on the BM tissue was negative.
To our knowledge, there were only three reported cases of T-cell PTLD following allogeneic HSCT and two cases following autologous HSCT. [2] [3] [4] These are summarized in Table 1 .
The pathogenesis of B-cell PTLD following allogeneic HSCT is thought to be due to unchecked proliferation of EBV-infected and immortalized B cells. 1 This leads to Bcell hyperplasia and eventually frank B-cell non-Hodgkin's lymphoma. The risk factors for PTLD development after allogeneic HSCT include T-cell depletion, HLA mismatching, antilymphocyte therapy and primary immunodeficiency as indication for HSCT. 5 Although more autologous HSCT are performed worldwide, PTLD occurs much less commonly in the autologous setting. 5 All cases of B-cell PTLD following autologous HSCT were of early onset and were EBV related, with high mortality (60%). 6, 7 In allogeneic HSCT, 480% of PTLD were of early onset. These were uniformly EBV related, with 80% mortality. 5 Hence, it can be concluded that B-cell PTLD following autologous and allogeneic HSCT have similar pathogenesis and clinical course.
T-cell PTLD following HSCT are exceedingly rare (Table 1 ). Time to PTLD diagnosis ranges from 1 to 43 months after the procedure. Only one case was shown to be EBV related. 3 Of note, no additional SC manipulation was performed in all reported cases. The pathology ranges from precursor to peripheral T-cell neoplasms. Although the number is small, it is tempting to speculate that PTLD in the form of T-LGL leukemia may have better prognosis than the T-lymphoma subtypes. Our patient has been well for more than 1 year despite persistent LGL lymphocytosis. HIV, CMV and EBV as possible etiologic agents, whereas others have also excluded human T-cell lymphotropic virus type I. 4 The present case of PTLD has a T-LGL phenotype. Expanded oligoclonal and even monoclonal populations of cytotoxic T cells have been detected in PB of patients with MM and smouldering myeloma. 8 These populations are thought to be the result of chronic persistent stimulation by tumor-associated antigens. Whether such antigenic stimulation, perhaps operating in an immunosuppressed host, can culminate in frank T-lymphoproliferative disorder is currently unknown.
In conclusion, T-cell PTLD can rarely occur after HSCT and these are mostly non-EBV associated. We know very little about the pathogenesis and clinical course. Further research is required to fully characterize the clinicopathologic features of this condition.
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